UK AI drug safety startup Sable Bio raises €3.15 million; plans to grow its London team

London-based Sable Bio has secured €3.2 million in seed funding, signalling significant investor confidence in its AI-powered approach to drug safety. This funding round, led by MMC Ventures with participation from Episode 1 Ventures and Seedcamp, will be instrumental in scaling Sable Bio's platform. The development is particularly noteworthy as it addresses a crucial gap in pharmaceutical R&D, where AI has seen substantial adoption in early discovery but lags in target safety assessment. Sable Bio's platform leverages bespoke AI models to extract safety-relevant information from millions of scientific papers and reports, employing causal inference methods to distinguish genuine safety signals from noise. This enables scientists to receive ranked insights highlighting critical concerns, thereby facilitating earlier risk mitigation. The company addresses a major bottleneck in the industry, where clinical trial failures, often due to unexpected toxicity, cost billions annually and still rely on increasingly inadequate manual data review processes. This advancement directly impacts pharmaceutical companies and biotechs, potentially reducing R&D costs and accelerating the development of safer, more effective drugs. By making comprehensive safety data accessible and actionable, Sable Bio aims to empower scientists to make faster, higher-confidence decisions, ultimately benefiting patients. The company's success in securing commercial agreements with major pharmaceutical firms underscores the growing demand for such AI-driven solutions in the sector. Sable Bio plans to utilize the new capital to expand its London team, enhance product development, and integrate real-world evidence, further solidifying its position in the competitive healthtech landscape.